NCT06506565 Low-Dose Ketamine Infusion During Burn Wound Care
| NCT ID | NCT06506565 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Tennessee |
| Condition | Burn |
| Study Type | INTERVENTIONAL |
| Enrollment | 140 participants |
| Start Date | 2024-07-08 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 140 participants in total. It began in 2024-07-08 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The current standard of care (SOC) (i.e. fentanyl and midazolam) offers limited efficacy for preventing or relieving pain. Ketamine infusions may provide the benefits of analgesia, minimize adverse events, and reduce opioid use. The purpose of this study is to determine if adding a low dose ketamine infusion during wound care will safely provide pain relief for patients with burn injury.
Eligibility Criteria
Inclusion Criteria: * Admitted to burn service with thermal injury Exclusion Criteria: * unable/unwilling to consent within 72 hours * unable to report NRS * known contraindication to ketamine * \< than 18 years of age * pregnant * incarcerated * TBSA over 50 %
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06506565 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Burn. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06506565 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06506565 currently recruiting?
Yes, NCT06506565 is actively recruiting participants. Contact the research team at dhill19@uthsc.edu for enrollment information.
Where is the NCT06506565 trial being conducted?
This trial is being conducted at Memphis, United States.
Who is sponsoring the NCT06506565 clinical trial?
NCT06506565 is sponsored by University of Tennessee. The trial plans to enroll 140 participants.